Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model
- 11 January 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 131 (2) , 236-246
Abstract
Thalassemias are a heterogeneous group of red blood cell disorders, considered as major cause of morbidity and mortality among genetic diseases. However, there is still no universally available cure for thalassemias. The underlying basis of thalassemia pathology is the premature apoptotic destruction of erythroblasts causing ineffective erythropoiesis. In β-thalassemia, β-globin synthesis is reduced causing α-globin accumulation. Unpaired globin chains, with heme attached to them, accumulate in thalassemic erythroblasts causing oxidative stress and the premature cell death. We hypothesize that in β-thalassemia heme oxygenase 1 (HO-1) could play a pathogenic role in the development of anemia and ineffective erythropoiesis. To test this hypothesis, we exploited a mouse model of β-thalassemia intermedia, Th3/+. We observed that HO inhibition using tin protoporphyrin IX (SnPP) decreased heme-iron recycling in the liver and ameliorated anemia in the Th3/+ mice. SnPP administration led to an increase in erythropoietin (EPO) and hepcidin serum levels, changes that were accompanied by an alleviation of ineffective erythropoiesis in Th3/+ mice. Additionally, the bone marrow from Th3/+ mice treated with SnPP exhibited decreased heme catabolism and diminished iron release as well as reduced apoptosis. Our results indicate that the iron released from heme due to HO activity contributes to the pathophysiology of thalassemia. Therefore, new therapies that suppress heme catabolism may be beneficial in ameliorating the anemia and ineffective erythropoiesis in thalassemias. Key points Iron released from heme by heme oxygenase 1 contributes to the pathophysiology of thalassemia. Inhibition of heme oxygenase 1 is of therapeutic value for the treatment of thalassemia.Keywords
This publication has 64 references indexed in Scilit:
- Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in miceJournal of Clinical Investigation, 2013
- An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermediaBlood, 2013
- Antidiabetic Potential of the Heme Oxygenase-1 Inducer Curcumin AnaloguesBioMed Research International, 2013
- Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemiaBlood, 2012
- Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overloadJournal of Clinical Investigation, 2011
- Stress erythropoiesis: new signals and new stress progenitor cellsCurrent Opinion in Hematology, 2011
- Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivoProceedings of the National Academy of Sciences, 2009
- Pharmacological and Clinical Aspects of Heme OxygenasePharmacological Reviews, 2008
- EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblastsBlood, 2007
- Regulation of protein synthesis by the heme-regulated eIF2α kinase: relevance to anemiasBlood, 2006